World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 October 2017
Main ID:  NCT00547521
Date of registration: 19/10/2007
Prospective Registration: Yes
Primary sponsor: Bristol-Myers Squibb
Public title: Phase IIIB Subcutaneous Abatacept Monotherapy Study
Scientific title: A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate
Date of first enrolment: December 2007
Target sample size: 119
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT00547521
Study type:  Interventional
Study design:   
Phase:  Phase 3
Countries of recruitment
Australia Brazil Canada Mexico Peru South Africa United States
Contacts
Name:     Bristol-Myers Squibb
Address: 
Telephone:
Email:
Affiliation:  Bristol-Myers Squibb
Key inclusion & exclusion criteria

Inclusion Criteria:

- Clinical diagnosis of Rheumatoid Arthritis

- Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog
scale

- Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except
for methotrexate

Exclusion Criteria:

- Received treatment with rituximab

- Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba
columns), mycophenolate mofetil (CellceptĀ®), cyclosporine A or other calcineurin
inhibitors, or D-Penicillamine



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis (RA)
Intervention(s)
Drug: abatacept
Drug: Methotrexate (MTX)
Primary Outcome(s)
Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for ELISA Results) [Time Frame: Baseline and on day 15, 29, 43, 57, 85 and 113]
Cross Tabulations of the Number of Participants With Positive and Negative Immunogenicity Status at Baseline and Each Visit During the ST Study (for MSD Results) [Time Frame: Baseline and day 15, 29, 43, 57, 85 and 113.]
Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for ELISA Results) [Time Frame: Day 113.]
Immunogenicity in MTX Naive and MTX-previous Users in Cohort 1 at Day 113 of the ST Study (for MSD Results) [Time Frame: Day 113.]
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (ELISA Method) Over Time During the ST Study [Time Frame: Day 15, 29, 43, 57, 85,113 and 28, 56, and 85 days post last dose.]
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses (Enzyme-linked Immunosorbent Assay [ELISA] Method) at Day 113 of the ST Study [Time Frame: Day 113]
Number of Participants With Positive Anti-abatacept Responses to Abatacept (Meso-Scale Discovery [MSD] Electrochemiluminescence [ECL] Assay Method) Over Time During the ST Study [Time Frame: Day 15, 29, 43, 57, 85,113 and 28, 56 and 85 days post last dose.]
Secondary Outcome(s)
Change From Baseline in All HAQ-DI Components at End of the 4-month Treatment Period (Day 113) of the ST Study [Time Frame: Baseline and Month 4 (Day113).]
Change From Baseline in DAS28-CRP Score and Physical Function (HAQ-DI) Score in the LTE Study - Abatacept Monotherapy Subgroup [Time Frame: Baseline, Day 113, Day 1345]
Change From Baseline in DAS28-CRP Score at End of 4-month (Day 113) of the ST Study [Time Frame: Baseline and Month 4 (Day113).]
Change From Baseline in DAS28-CRP Score in the LTE Study - All Treated Participants in LTE Study [Time Frame: Baseline, Day 113, Day 1345]
Change From Baseline in HAQ-DI in the LTE Study - All Treated Participants in LTE Study [Time Frame: Baseline, Day 113, Day 1345]
Change From Baseline in Physical Functioning (HAQ-DI) at End of the 4-month Treatment Period (Day 113) of the ST Study [Time Frame: Baseline and Month 4 (Day 113).]
Cross Tabulations of Number of Participants With Positive and Negative Status for RF at Day 113 With Baseline, in the ST Study [Time Frame: Baseline and Day 113.]
Minimum Plasma Concentration (Cmin) at Each Visit During the 4 Month Treatment Period of the ST Study [Time Frame: Days 1, 15, 29, 43, 57, 85 and 113.]
Number of Participants in DAS 28-CRP Remission and Low Disease Activity (LDA) in the LTE Study - Abatacept Monotherapy Subgroup [Time Frame: Day 113, Day 1345]
Number of Participants in DAS28-CRP Remission and Number of Participants With Low Disease Activity (LDA) in the LTE Study - All Treated Participants in the LTE [Time Frame: Day 113, Day 1345]
Number of Participants Who Died, Experienced SAEs, Experienced AEs or Who Discontinued Due to AEs During the ST Study [Time Frame: Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.]
Number of Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs), or Discontinued Due to AEs and/or SAEs During the LTE Period - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE Study up to 56 days post the last dose]
Number of Participants Who Experienced Drug-related SAEs and Drug-related AEs During the ST Study [Time Frame: Continuously through ST period (upto Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.]
Number of Participants With Abatacept Induced Antibody Responses Over Time During the LTE Study (ECL Method) - All Treated Participants in LTE Study [Time Frame: Days 197, 281, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541, 1625, 1709, 1821, 1989, days post dose: 28, 56, 85, 168]
Number of Participants With AEs of Special Interest During the LTE Study - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE Study up to 56 days post the last dose]
Number of Participants With AEs of Special Interest During the ST Study [Time Frame: Continuously through ST period (up to Day 113). Includes the data from start of study drug therapy up to 56 days after the last dose (Day 113) or start of the long-term period whichever occurred first.]
Number of Participants With Anti-double Stranded DNA (dsDNA) Category at Day 113 of the ST Study [Time Frame: Day 113.]
Number of Participants With Anti-nuclear Antibody (ANA) Category at Day 113 of the ST Study [Time Frame: Day 113.]
Number of Participants With Clinically Meaningful Improvement at End of 4-month (Day 113) of the ST Study [Time Frame: Day 113.]
Number of Participants With Clinically Meaningful Improvement From Baseline in the LTE Study - All Treated Participants in LTE Study [Time Frame: Baseline, Day 113, Day 1345]
Number of Participants With Clinically Meaningful Vital Signs During the ST Study [Time Frame: At screening and on days 1,15,29,43, 57, 85 and 113.]
Number of Participants With HAQ Responses in the LTE Study - All Treated Participants in the LTE STudy [Time Frame: Baseline, Day 113, Day 1345]
Number of Participants With Marked Abnormalities (MAs) in Hematology During the LTE Period - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE Study up to 56 days post the last dose]
Number of Participants With Marked Abnormalities (MAs) in Hematology During the ST Study: Hemoglobin, Hematocrit, Platelet Count, Erythrocytes and Leukocytes [Time Frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.]
Number of Participants With MAs in Hematology During the ST Study: Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute) [Time Frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.]
Number of Participants With MAs in Serum Chemistry (Electrolytes, Glucose, Protein, and Metabolite) During the LTE Period - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE Study up to 56 days post the last dose]
Number of Participants With MAs in Serum Chemistry (Liver and Kidney Function) During the LTE Period - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE Study up to 56 days post the last dose]
Number of Participants With MAs in Serum Chemistry During the ST Study: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Bilirubin (Total), G-Glutamyl Transferase (G-GT) and Blood Urea Nitrogen (BUN) [Time Frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.]
Number of Participants With MAs in Serum Chemistry During the ST Study: Creatinine, Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total) and Protein (Total) [Time Frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.]
Number of Participants With MAs in Serum Chemistry During the ST Study: Glucose (Fasting Serum), Albumin, Glucose (Serum), Phosphorous (Inorganic) and Uric Acid [Time Frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.]
Number of Participants With MAs in Urinalysis During the LTE Period: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE Study up to 56 days post the last dose]
Number of Participants With MAs in Urinalysis During the ST Study: Protein, Glucose, Blood, Leukocyte Esterase, Red Blood Cells (RBC) and White Blood Cells (WBC) [Time Frame: Continuously from start of ST period up to 56 days post the last dose in the short-term period or start of the long-term period, whichever occurred first.]
Number of Participants With Negative Status for RF up to 7 Days After Last Dose of Abatacept in the LTE Period - All Treated Participants in LTE Study [Time Frame: Continuously from start of LTE period up to 7 days post the last dose]
Secondary ID(s)
IM101-173
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 24/01/2011
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT00547521
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history